Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6750166 | 0.88 | HPGD (0.45) | HPGDKDM4EPKMGPR119FAAH | |
| SCHEMBL15247425 | 0.88 | HPGD (0.45) | HPGDKDM4EPKMGPR119FAAH | |
| SCHEMBL9389313 | 0.87 | HPGD (0.44) | HPGDKDM4EPKMGPR119FAAH | |
| SCHEMBL9891004 | 0.85 | GAA (0.39) | GAAMEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL8631686 | 0.84 | KDM4E (0.44) | HPGDKDM4EPKMGPR119FAAH | |
| SCHEMBL21994475 | 0.81 | HPGD (0.46) | HPGDKDM4EPKMGPR119FAAH | |
| SCHEMBL22233243 | 0.81 | HPGD (0.46) | HPGDKDM4EPKMGPR119FAAH | |
| SCHEMBL15143956 | 0.80 | HPGD (0.53) | HPGDKDM4EPKMGPR119FAAH | |
| SCHEMBL1721300 | 0.80 | FAAH (0.47) | HPGDKDM4EPKMGPR119FAAH | |
| SCHEMBL6156540 | 0.80 | GPR119 (0.53) | HPGDKDM4EPKMGPR119GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142722-A1 | CONJUGATES OF CYTOTOXIC DRUGS | APOSENSE LTD. (IL) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142722-A1 | CONJUGATES OF CYTOTOXIC DRUGS | CD47, MCL1, BAD | HPGD 1690/4885KDM4E 1405/4885PKM 2761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.